Compare GH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | TMDX |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 4.6B |
| IPO Year | 2018 | 2019 |
| Metric | GH | TMDX |
|---|---|---|
| Price | $84.39 | $122.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | $117.80 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.6M | 791.1K |
| Earning Date | 05-11-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.74 | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | ★ $982,021,000.00 | $605,494,000.00 |
| Revenue This Year | $33.40 | $24.12 |
| Revenue Next Year | $28.55 | $18.69 |
| P/E Ratio | ★ N/A | $26.48 |
| Revenue Growth | 32.88 | ★ 37.13 |
| 52 Week Low | $36.36 | $62.42 |
| 52 Week High | $120.74 | $156.00 |
| Indicator | GH | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 27.18 | 37.25 |
| Support Level | $54.39 | $106.27 |
| Resistance Level | $114.53 | $128.96 |
| Average True Range (ATR) | 4.54 | 8.92 |
| MACD | -0.83 | -1.85 |
| Stochastic Oscillator | 10.30 | 2.52 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.